EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 477775-14-7, Compound 21, At2 agonist c21, Buloxibutid, At2 receptor agonist c21, M 24

Molecular Formula

C₂₃H₂₉N₃O₄S₂

Molecular Weight

475.6 g/mol

InChI Key

XTEOJPUYZWEXFI-UHFFFAOYSA-N

FDA UNII

RC2V4W0EYC

1 2D Structure

Buloxibutid

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate

2.1.2 InChI

InChI=1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27)

2.1.3 InChI Key

XTEOJPUYZWEXFI-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C=CN=C3

2.2 Other Identifiers

2.2.1 UNII

RC2V4W0EYC

2.3 Synonyms

2.3.1 MeSH Synonyms

1. C-21

2. C-21 Sodium

3. C21

4. C21 Sodium

5. Compound 21

6. Compound 21 Sodium

2.3.2 Depositor-Supplied Synonyms

1. 477775-14-7

2. Compound 21

3. At2 Agonist C21

4. Buloxibutid

5. At2 Receptor Agonist C21

6. M 24

7. C-21

8. Rc2v4w0eyc

9. Chembl189568

10. T2 Agonist Compound 21

11. Compound 21 [pmid: 22802221]

12. M-24

13. Butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate

14. Butyl 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-ylsulfonylcarbamate

15. Butyl ((3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate

16. N-[[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]carbamic Acid Butyl Ester

17. Butyl [3-[4-[(1h-imidazol-1-yl)methyl]phenyl]-5-isobutylthiophen-2-yl]sulfonylcarbamate

18. Carbamic Acid, ((3-(4-(1h-imidazol-1-ylmethyl)phenyl)-5-(2-methylpropyl)-2-thienyl)sulfonyl)-, Butyl Ester

19. Carbamic Acid, [[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]-, Butyl Ester

20. Buloxibutid [inn]

21. 3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(n-butyloxylcarbamate)-sulphonamide] Sodium Salt

22. Unii-rc2v4w0eyc

23. Schembl557591

24. Gtpl6918

25. C 21 [who-dd]

26. Xteojpuyzwexfi-uhfffaoysa-n

27. Bcp30872

28. Cua77514

29. Bdbm50156173

30. Akos030231077

31. At18254

32. Sb18730

33. Ncgc00386668-01

34. M024/c21

35. Ms-28827

36. Ds-017243

37. Hy-100113

38. Cs-0018094

39. M-024

40. M 24;m-24;m24;c-21

41. Q27076423

42. N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide

43. (1-((2''-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol

44. Butyl [3-{4-[(1h-imidazol-1-yl)methyl]phenyl}-5-(2-methylpropyl)thiophene-2-sulfonyl]carbamate

45. Butyl N-{3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-ylsulfonyl}carbamate

46. Carbamic Acid, [[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfon Yl]-, Butyl Ester

47. Carbamic Acid,[[3-[4-(1h-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]-, Butyl Ester

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₉N₃O₄S₂
Molecular Weight	475.6 g/mol
XLogP3	5.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	11
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	127
Heavy Atom Count	32
Formal Charge	0
Complexity	690
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Anti-Inflammatory Agents

Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find Drugs in Development News & Deals for Buloxibutid

Buloxibutid

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?